Our drug candidates are derived from in-house R&D and our collaborations with reference research centers and other companies. We have several proprietary programs developing in multiple therapeutic areas, including immune-oncology, which is a high-growth area for companies and investors. LeadArtis offers an opportunity to participate in the development of cutting-edge immunomodulatory therapies against cancer.

 

By creating new medicines, we can create hope for future patients suffering from cancers for which current therapies are inadequate. 

 

Trimerbody® is a registered trademark and is covered by international patents.